Market Closed - London S.E. 11:35:23 2024-04-24 am EDT 5-day change 1st Jan Change
28.5 GBX +0.88% Intraday chart for hVIVO plc +3.26% +20.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024
HVIVO swings to profit and commences annual dividends as outlook rosy AN
HVIVO plc Provides Revenue Guidance for the Year 2024 CI
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024
HVIVO plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Green Transition starts trading on London's AIM market AN
Investment firm European Green Transition plans listing on AIM AN
HVIVO Chair and non-exec director sell 30.0 million shares AN
Hvivo Completes Secondary Placing MT
HVIVO directors to sell total of 14 million shares AN
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares MT
Transcript : HVIVO plc, Q4 2023 Sales/ Trading Statement Call, Jan 30, 2024
FTSE 100 Ends on Three-Week High, Partly on Diageo Rebound DJ
HVIVO shares up after "record year" across all metrics AN
Hvivo Wins GBP6 Million Antiviral Testing Contract MT
HVIVO inks GBP6.3 million deal to test common cold treatment AN
New Year begins largely green amid slew of PMIs AN
HVIVO plc Signs £6.3 Million Human Challenge Study Model CI
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges MT
HVIVO signs deal to test RSV antiviral drug candidate with study model AN
HVIVO celebrates positive results for Pneumagen's Neumifil in trial AN
HVIVO interim profit jumps on revenue increase; ups full-year guidance AN
HVIVO raises 2023 revenue view on demand for respiratory therapy testings RE
UK Stocks-Factors to watch on Sept 12 RE
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M MT
Chart hVIVO plc
More charts
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.285 GBP
Average target price
0.3607 GBP
Spread / Average Target
+26.56%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. VENN Stock
  4. News hVIVO plc
  5. Open Orphan : Says UK Government to Expand COVID-19 Characterization Study; Shares Up 7%